Esmaeli Mojtaba, Dehghanpour Dehabadi Maryam
Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran.
Med Oncol. 2025 Jun 3;42(7):237. doi: 10.1007/s12032-025-02790-6.
Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has gained significant attention for its potential therapeutic effects across various types of cancer. This manuscript presents a systematic review of the current evidence on the application of CBD in gastrointestinal (GI) malignancies, with a focus on gastric and colorectal cancers. The review aims to explore CBD's mechanisms of action, including its effects on apoptosis, cell cycle regulation, angiogenesis, inflammation, and its potential to enhance the efficacy of conventional therapies. Furthermore, it examines the challenges involved in translating preclinical findings into clinical settings, such as issues related to bioavailability and regulatory hurdles. The review also addresses future directions for the use of CBD in combination therapies and its potential to overcome resistance mechanisms in GI cancers. By analyzing the molecular pathways modulated by CBD, this manuscript seeks to offer a comprehensive understanding of its therapeutic potential, contributing to the future of GI cancer treatment.
大麻二酚（CBD）是一种从大麻中提取的无精神活性化合物，因其在各类癌症中潜在的治疗作用而备受关注。本手稿对目前CBD在胃肠道（GI）恶性肿瘤应用方面的证据进行了系统综述，重点关注胃癌和结直肠癌。该综述旨在探索CBD的作用机制，包括其对细胞凋亡、细胞周期调控、血管生成、炎症的影响，以及增强传统疗法疗效的潜力。此外，它还研究了将临床前研究结果转化为临床应用所涉及的挑战，如生物利用度相关问题和监管障碍。该综述还探讨了CBD在联合治疗中的未来应用方向及其克服GI癌症耐药机制的潜力。通过分析CBD调节的分子途径，本手稿力求全面了解其治疗潜力，为GI癌症治疗的未来发展做出贡献。
